Be The Match BioTherapies® and Kiadis Pharma Announce Strategic Collaboration to Accelerate Patient Access to Haploidentical...
22 Maio 2019 - 1:00PM
Collaboration will
support Phase III clinical trial of cell therapy product
ATIR101(TM) for blood cancers
MINNEAPOLIS & AMSTERDAM, May 22, 2019 - Be The Match
BioTherapies®, an organization offering solutions for companies
developing and commercializing cell and gene therapies, and Kiadis
Pharma N.V. ("Kiadis") (Euronext Amsterdam and Brussels: KDS),
a clinical stage biopharmaceutical company, today announced a
strategic collaboration to support clinical evaluation of an
innovative cell therapy product with potential to make
haploidentical hematopoietic stem cell transplantations (HSCT)
safer and more effective for patients.
Under the terms of the collaboration agreement, Be The Match
BioTherapies will provide logistical and technological solutions to
support Kiadis' Phase III clinical trial for ATIR101, an adjunctive
immunotherapeutic designed to address key risks and limitations of
HSCT in the treatment of blood cancers.
Kiadis' multinational Phase III clinical trial is evaluating the
safety and efficacy of ATIR101 as an adjunctive treatment to HSCT
from a half-matched (haploidentical) family donor compared to
post-transplant cyclophosphamide (PTCy or "Baltimore" protocol) in
adult patients with blood cancers. The Phase III study is currently
enrolling patients in the EU, Canada, Israel and the U.S.
The collaboration will leverage Be The Match BioTherapies'
industry-leading expertise in cell delivery logistics and supply
chain case management, including the company's MatchSource® end-to-end supply chain management software, to
manage the transport and processing of cellular products for use at
Kiadis' clinical trial sites in the U.S. and Canada.
"Kiadis' quest to provide better treatment outcomes for patients
receiving stem cell transplants is one we deeply share, given the
foundational role that our parent company, the National Marrow
Donor Program®/Be The
Match®, has played
in improving stem cell transplantation for more than three
decades," said Chris McClain, vice president of Sales and New
Business Development, Be The Match BioTherapies. "We look forward
to utilizing our cell therapy expertise to advance Kiadis'
important work."
"We're pleased to partner with Be The Match BioTherapies to
progress our clinical investigation of ATIR101 and to expedite its
availability to patients," said Andrew Sandler, chief medical
officer of Kiadis Pharma. "We believe this therapeutic approach
could allow family members to serve as stem cell donors for those
patients who would otherwise not find a matching donor in time,
ultimately saving lives."
Media Contacts:
Be The Match BioTherapies:
Stephanie Simon
Ten Bridge Communications
+1 (617) 581-9333
stephanie@tenbridgecommunications.com
Kiadis Pharma:
Maryann Cimino, Manager, Corporate Affairs
+1 (617) 710-7305
m.cimino@kiadis.com
Optimum Strategic Communications:
Mary Clark, Supriya Mathur, Hollie Vile
Tel: +44 203 950 9144
David Brilleslijper (Amsterdam)
Tel: +31 610 942 514
kiadis@optimumcomms.com
About Kiadis
Founded in 1997, Kiadis Pharma, is a fully integrated
biopharmaceutical company committed to developing innovative
therapies for patients with late-stage blood cancers. With
headquarters in Amsterdam, the Netherlands, Kiadis Pharma is
reimagining medicine by leveraging the natural strengths of
humanity and our collective immune system to source the best cells
for life.
Kiadis Pharma is listed on the regulated market of Euronext
Amsterdam and Euronext Brussels since July 2, 2015, under the
symbol KDS. Learn more at kiadis.com
About ATIR101
ATIR101TM is an
investigational allodepleted T-cell immunotherapy product
candidate, which is designed to be given after a haploidentical
(genetically half-matched) hematopoietic stem cell transplantation
(HSCT).
Administered as an adjunctive immunotherapeutic on top of HSCT,
ATIR101 provides a single dose donor lymphocyte infusion (DLI) with
functional, mature immune cells from a haploidentical family
member. The T-cells in ATIR101 will help fight infections and
remaining tumor cells, until the immune system has fully re-grown
from stem cells in the transplanted graft.
In ATIR101, T-cells that would cause GVHD are depleted from the
donor lymphocytes, using our photodepletion technology. At the same
time, ATIR101 contains potential cancer-killing T-cells from the
donor that could eliminate residual cancer cells and help prevent
relapse of the disease.
About Be The Match BioTherapies®
Be The Match BioTherapies is the only cell and
gene therapy solutions provider with customizable services to
support the end-to-end cell therapy supply chain. Backed by the
industry-leading experience of the National Marrow Donor
Program®/Be The
Match®, and a
research partnership with the CIBMTR® (Center
for International Blood and Marrow Transplant Research®), the
organization designs solutions that advance cell and gene therapies
in any stage of development.
Be The Match BioTherapies is dedicated to providing high-quality
cellular starting material consented for research, clinical and
commercial use, developing and managing expansive cell collection
networks, and navigating cell therapy regulatory compliance. Using
proven infrastructure to successfully manage cell therapy supply
chains, including MatchSource®
Supply Chain Software, dedicated cell therapy supply chain case
managers and logistics experts, the organization has a history of
compliance managing the chain of identity. The collaboration with
CIBMTR extends services to include long-term follow-up tracking for
the first two FDA-approved CAR-T therapies.
For more information, follow Be The Match BioTherapies
on LinkedIn or Twitter at @BTMBioTherapies.
Kiadis Forward-Looking Statements
Certain statements, beliefs and opinions in this press release are
forward-looking, which reflect Kiadis Pharma's or, as appropriate,
Kiadis Pharma's directors' current expectations and projections
about future events. By their nature, forward-looking statements
involve a number of risks, uncertainties and assumptions that could
cause actual results or events to differ materially from those
expressed or implied by the forward-looking statements. These
risks, uncertainties and assumptions could adversely affect the
outcome and financial effects of the plans and events described
herein. A multitude of factors including, but not limited to,
changes in demand, regulation, competition and technology, can
cause actual events, performance or results to differ significantly
from any anticipated development. Forward-looking statements
contained in this press release regarding past trends or activities
should not be taken as a representation that such trends or
activities will continue in the future. As a result, Kiadis Pharma
expressly disclaims any obligation or undertaking to release any
update or revisions to any forward-looking statements in this press
release as a result of any change in expectations or any change in
events, conditions, assumptions or circumstances on which these
forward-looking statements are based. Neither Kiadis Pharma nor its
advisers or representatives nor any of its subsidiary undertakings
or any such person's officers or employees guarantees that the
assumptions underlying such forward-looking statements are free
from errors nor does either accept any responsibility for the
future accuracy of the forward-looking statements contained in this
press release or the actual occurrence of the forecasted
developments. You should not place undue reliance on
forward-looking statements, which speak only as of the date of this
press release.
This
announcement is distributed by West Corporation on behalf of West
Corporation clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Kiadis Pharma N. V. via Globenewswire